Protara Therapeutics, Inc. (NASDAQ:TARA) Receives $20.40 Consensus Target Price from Analysts

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) have been given a consensus rating of "Buy" by the six ratings firms that are currently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have covered the stock in the last year is $20.40.

Several brokerages recently commented on TARA. Cantor Fitzgerald began coverage on Protara Therapeutics in a report on Friday, March 14th. They set an "overweight" rating on the stock. Scotiabank began coverage on Protara Therapeutics in a report on Wednesday, April 16th. They set a "sector outperform" rating and a $12.00 target price on the stock. HC Wainwright reiterated a "buy" rating and set a $23.00 target price on shares of Protara Therapeutics in a report on Monday, April 28th. Finally, Lifesci Capital began coverage on Protara Therapeutics in a report on Tuesday, March 11th. They set an "outperform" rating and a $22.00 target price on the stock.

Insiders Place Their Bets

In other Protara Therapeutics news, insider Jacqueline Zummo sold 21,224 shares of Protara Therapeutics stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total transaction of $96,144.72. Following the sale, the insider now directly owns 98,861 shares in the company, valued at $447,840.33. The trade was a 17.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 12.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Protara Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of TARA. Charles Schwab Investment Management Inc. purchased a new stake in Protara Therapeutics during the 1st quarter worth approximately $64,000. HBK Investments L P bought a new stake in shares of Protara Therapeutics in the 4th quarter valued at approximately $106,000. Squarepoint Ops LLC bought a new stake in shares of Protara Therapeutics in the 4th quarter valued at approximately $110,000. Dimensional Fund Advisors LP bought a new stake in shares of Protara Therapeutics in the 4th quarter valued at approximately $111,000. Finally, American Century Companies Inc. bought a new stake in shares of Protara Therapeutics in the 1st quarter valued at approximately $154,000. 38.13% of the stock is currently owned by hedge funds and other institutional investors.

Protara Therapeutics Stock Down 1.4%

Shares of NASDAQ TARA traded down $0.05 during midday trading on Friday, hitting $3.09. The stock had a trading volume of 109,386 shares, compared to its average volume of 775,794. The company has a market capitalization of $119.03 million, a price-to-earnings ratio of -1.09 and a beta of 1.73. Protara Therapeutics has a 1-year low of $1.60 and a 1-year high of $10.48. The company has a fifty day moving average price of $3.96 and a 200 day moving average price of $4.11.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.18. On average, research analysts forecast that Protara Therapeutics will post -3.32 EPS for the current year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.